Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs)
$138.82
neg -1.64
-1.17%
Today's Range: 138.18 - 140.78 | AMGN Avg Daily Volume: 3,085,200
Last Update: 10/01/14 - 4:14 PM EDT
Volume: 3,747,981
YTD Performance: 23.12%
Open: $140.39
Previous Close: $140.46
52 Week Range: $105.76 - $144.46
Oustanding Shares: 759,607,230
Market Cap: 106,398,184,706
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 6 8
Moderate Buy 2 2 2 1
Hold 8 8 9 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.17 2.15 2.08
Latest Dividend: 0.61
Latest Dividend Yield: 1.74%
Dividend Ex-Date: 08/12/14
Price Earnings Ratio: 21.45
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
21.45 21.50 28.41
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.66% 25.49% 155.57%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.20 0.24 0.07
Net Income 16.90 0.10 0.03
EPS 20.30 0.40 0.12
Earnings for AMGN:
EBITDA 7.35B
Revenue 18.68B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $2.07 $2.17 $8.24 $8.89
Number of Analysts 3 2 2 2
High Estimate $2.10 $2.24 $8.37 $9.22
Low Estimate $2.01 $2.11 $8.12 $8.56
Prior Year $1.93 $1.81 $7.57 $8.24
Growth Rate (Year over Year) 7.25% 20.17% 8.92% 7.82%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Update
Sep 10, 2014 | 7:39 AM EDT
Morgan Stanley Healthcare Conference

Bionic or Just Plain? Real Money Pro($)

Checking two biotech charts.
Amgen's gain is pure insanity from a stock picker's point of view.
These quality names look appealing on the basis of 30-week moving average.
Bullish
Jul 30, 2014 | 7:13 AM EDT
Shares of AMGN now seen reaching $135, according to Credit Suisse. Estimates also increased, given the company's new guidance. Neutral ...
On a daily time frame, as long as it holds a key support level, it's a possible buy.
Hologic, Symantec and TE Connectivity could all benefit from the current M&A binge.
For now, just let the market do the heavy lifting for you.

Biotechs Flash the Green Light Real Money Pro($)

After a decline, the sector has built a base, and these names are breaking out.
Spice up your portfolio with some takeover bait.

Columnist Conversations

The Russell 2000 has led the broader market lower and today it returned to its 2014 lows, the bottom end of a ...
Here are the next potential support decisions to watch in SPX cash. Note that the current decline is only sim...
I have been monitoring the price action of Amazon (AMZN) within the symmetrical triangle formation on its week...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.